PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Ikena Oncology, Inc.

USPTO PatentsView assignee record - 14 granted patents across 6 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (HETEROCYCLIC COMPOUNDS).

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ikena ranks #19,890 of 50,000 tracked US assignees by granted-patent volume, with 14 patents across 6 technology areas.

#19,890
of 50,000 US assignees by volume
Top 12%
by Innovation Score (51.3/100)
22.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R19890 · US Corporation #19,890 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 14 grants
  • MID-PACK #19,890/50,000
  • PHOTO-FINISH Igneous Systems
  • CPC-NARROW C07D · 6 areas
  • INNOV-PAR 51.3/100
  • CLAIMS-DENSE 22.1 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2020–2024 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Igneous Systems, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Ikena

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Ikena Oncology, Inc. stamps GRANTS-MICRO, MID-PACK, PHOTO-FINISH, CPC-NARROW, INNOV-PAR, CLAIMS-DENSE, TYPE-USCORP, SPAN-YRS, BOOK-RICH. Volume places it #19,890 of 50,000; Innovation Score 51.3/100 sits in the top 12% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Igneous Systems, Inc. (±0 grants).

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Portfolio overview

Ikena Oncology, Inc. has been granted 14 US utility patents between 2020 and 2024, placing Ikena Oncology, Inc. at #19,890 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.1 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a US Corporation, Ikena Oncology, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Ikena sits between ITN Energy Systems, Inc. (14 patents, rank #19,913) and Incelldx, Inc. (14 patents, rank #19,921) - the closest US assignees by grant volume. The composite Innovation Score of 51.3/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2020 through 2024, with 14 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Ikena Oncology, Inc.'s 22.1 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 6 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Ikena's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Ikena holds 14 patents at rank #19,917, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Ikena

By rank, the assignees closest to #19,917 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Ikena's primary technology class.

Ikena's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

123456 2020202220232024 5
USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Ikena Oncology, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 2 14.3%
2022 3 21.4%
2023 4 28.6%
2024 5 35.7%

Which technologies does Ikena Oncology, Inc. patent most?

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#19,890

of 50,000 tracked assignees

Innovation Score

51.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.